The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

Br J Haematol. 2012 May;157(3):401-3. doi: 10.1111/j.1365-2141.2011.08998.x. Epub 2012 Jan 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Central Nervous System Neoplasms / prevention & control*
  • Drug Evaluation / methods
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Rituximab
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab